Biotest AG and Lonza Enter into Manufacturing Agreement
21-Feb-2005
BT-061 is directed against a novel target on T-cells mediating a unique, immunoregulatory mechanism of action. The candidate is Biotest´s most advanced monoclonal antibody and has shown tolerability and efficacy in early clinical trials in patients with rheumatoid arthritis. With the clinical material produced by Lonza Biologics, Slough, UK, development will continue in rheumatoid arthritis and psoriasis.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.